|
Market Cap (5-Jul) $6,838,995 (1,207th) |
Close (30-Jun) $0.200 |
Volume (30-Jun) 1,808,064 |
Shortsold (12-Jun) 8,499 (0.01%) (521st) |
|
52w High $0.100 |
52w Low $0.059 |
P/E - |
EPS 0 |
IXC released this announcement to the ASX on 8 March 2021, 9:12. The announcement is not marked as price sensitive, and is 16 page(s) in length and 885.39kb in size.
You can view all announcements from IXC and see how they appear on a price chart on the announcements page.
At the date of this announcement, IXC was 0.552% short sold according to ASIC data. It was ranked the 263rd most shorted stock on the ASX. It remains ranked 521st as of the latest reported data (12 June 2025).
| Other Recent Announcements from IXC | |
|---|---|
| Phase III Clinical Trial Update and New IIH Market Analysis | 28 June 2023, 8:40 |
| Invex Granted European Orphan Drug Designation for TBI | 23 June 2023, 8:18 |
| Invex Receives Regulatory Approval for IIH EVOLVE in France | 21 April 2023, 8:17 |
| Notice of General Meeting/Proxy Form | 8 March 2021, 9:12 |
| US Trademark Granted for Presendin | 26 February 2021, 8:50 |
| Initial Director's Interest Notice | 16 February 2021, 13:11 |
| Invex Appoints Dr Megan Baldwin as Non-Executive Director | 16 February 2021, 8:37 |
You must be logged in to post a reply.
Invex Therapeutics Ltd 